- Email: [email protected]
5158038 Egg injection method, apparatus and carrier solution for improving hatchability and disease control
New Patents
5156960 MICROBIAL PROCESS FOR THE PRODUCTION OF IMMUNOSUPPRESSIVE ANTIBIOTICS nee Bokany Antonia Jekkel, Gabor Ambrus, Eva Toth-Sarudy, Istvan Mihaly, nee Dobos Agota Huiber, Attil Andor, Karol Albrecht, Kalman Konczol, Valeri Szell, nee Joszt Eva Tomori, Imre Moravcsik, Kalman Polya, Jano Erdei, Lajos Kiss, Bela Makadi, Karoly Nagy, Bel Palotas, nee Konszky Etelk Deli, Karoly Buzasi, nee Antal Aniko Santha Gyorgy Molnar, Vilma Szaszhegyesi, Budapest, Hungary assigned to Biogal Gyogyszergyar The invention relates to a microbial process for the production of immunosuppressive cyclosporine antibiotic complex or of its components, cyclosporine A, cyclosporine B and cyclosporine C, by the aerobic fermentation of a filamentous fungus strain biosynthesizing the above antibiotic(s) in a nutrient medium containing utilizable carbon and nitrogen sources as well as mineral salts, and by isolating the products formed, which comprises culturing a strain of the novel Tolypocladium varium fungus species producing the cyclosporine antibiotic complex, preferably tolypocladium varium sp. nov. CY/93, deposited at the National Collection of Agricultural and Industrial Microorganisms, Budapest, Hungary under the number NCAIM(P)F 001005, on a nutrient medium containing carbon sources, organic and inorganic nitrogen sources as well as mineral salts, under aerobic conditions, at 25 degrees to 30 degrees C., and, if desired, isolating and purifying the cyclosporine antibiotic complex or its components produced.
vii
of enhancing the activity of phagocytes including macrophages, and in a further variant, a method of modulating the cellular or humoral immune response to warm blooded animals. The invention also provides a method of reducing the adverse effects of stress in warm blooded animals. This is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M I-O-Y, an ethereal monosubstitution of monosaccharide derivatives having the general formula M2-O-Y, or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In the first variant, the above substances are administered in an amount effective to enhance the microbicidal activity of phagocytes, including macrophages in a normal to depressed state of activation or macrophages already activated in response to infection. In the second variant, the above substances are administered in an amount to enhance the cellular or humoral immune response when tile warm blooded animal has a normal or depressed cellular or humoral immune response system, or in an amount effective to reduce the cellular or humoral immune response when the warm blooded animal has a hypersensitive cellular or humoral immune response system. In the third variant, the above substances are administered in an amount effective to reduce the adverse effects of stress on the aforementioned defense mechanisms of warm blooded animals subjected to stress.
5158038 EGG INJECTION METHOD, APPARATUS AND CARRIER SOLUTION FOR IMPROVING HATCHABILITY AND DISEASE CONTROL Oliver B Sheeks, Raymond Sheeks
5157024 METHOD OF ENHANCING THE ACTIVITY OF PHAGOCYTES INCLUDING MACROPHAGES, MODULATING THE CELLULAR OR HUMORAL IMMUNE RESPONSE, AND REDUCING THE ADVERSE EFFECTS OF STRESS IN WARM BLOODED ANIMALS Pau Gordon assigned to Strategic Medical Research Corporation In one variant, the invention provides a method
An egg injection machine, beneficial injectable formulations for increasing the hatchability of avian hatchery eggs, and an improved method for the control of contamination in the injection process are provided. A novel ethanol-based contamination control carrier solution allows beneficial vaccines, vitamins, nutrients, and trace minerals to be injected into fertile eggs without risk of contamination of the eggs by machine, solution, or egg-to-egg crosscontamination by the injection needle. The invention is useful in both the chicken and turkey hatchery industry for egg injections prior to incubator setting or during transfer to hatch bins. Hatch improvements of + 2.29 percent to + 5.33
viii
New Patents
percent are shown for varying conditions. A method for facilitating the injections of virus vaccines is disclosed.
5158769 PRE-S GENE CODED PEPTIDE HEPATITIS B IMMUNOGENS, VACCINES, DIAGNOSTICS, AND SYNTHETIC LIPID VESICLE CARRIERS Alexander R Neurath, Stephen B Kent assigned to New York Blood Center Inc; California Institute of Technolo A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals. The peptides of the invention can be utilized in diagnostics for the detection of antigens and antibodies.
5158870 DIAGNOSTIC METHODS FOR MYCOPLASMA GENITALIUM INFECTIONS Joel B Baseman, Janice Morrison-Plummer assigned to Board of Regents The University of Texas System Monoclonal antibodies binding Mycoplasma genitalium more strongly than Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma orale, Mycoplasma salivarium and Acholeplasm laidlawii are described herein. These monoclonal antibodies are utilized in immunoassays directed toward the detection of M. genitalium infections. Hybridomas producing the above-described monoclonal anti-
bodies have been created and isolated. These monoclonal antibodies are directed toward M. genitalium antigens. Certain antibodies bind protein antigens, while others bind lipid antigens. In one case a particular antibody apparently has binding affinity for both protein and lipid antigens of M. genitalium.
5158884 IMMUNODOMINANT ACETYLCHOLINE RECEPTOR PEPTIDES USEFUL FOR THELPER CELL SENSITIZATION Bianca M Conti-Tronconi, Maria P Protti assigned to Regents of the University of Minnesota The present invention provides four synthetic peptides corresponding to subunits of the alphasubunit of the nicotinic acetyl choline receptor (AChR) which have formulas (1-4): (1) gln-il eval-thr-thr-asn-val-arg leu-lys-gln-gln-trp-valasp tyr-asn-leu-lys-trp; (2) ala-ile-val-lys-phe thr-lys-val-leu-leu-gln-tyrthr-gly-his-ile-thr-trpth r-pro; (3) ser-thr-his-val-met-pro-asn trp-valarg-lys-val-phe ile-asp-thr-ile-pro-as n; and (4) ile-ile-gly-thr-leu-ala val-phe-ala-gly-arg-leu-ile glu-leu-asn-gln-gln-gl y; as well as biologically active fragments thereof, and anti-AChR Thelper cell populations having receptor sites therefor.
5158940 USE OF SURAMIN TO TREAT RHEUMATOLOGIC DISEASES Renato LaRocca, Cy A Stein, Michael Cooper, Charles Myers assigned to The United States Government as represented by the Secretary DHHS Polysulfonated compounds such as suramin are used to treat immunoregulatory disorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.
5164320 METHOD FOR LYSING HARD LIPOSOMES USING POLYETHYLENEGLYCOL MONO-N-ALKYL ETHERS Herman Rutner, Abdul M Butt, Marie M Sylvestre, Josephine D Readio, Lewis Pollack assigned to Becton Dickinson and Company
5156960 MICROBIAL PROCESS FOR THE PRODUCTION OF IMMUNOSUPPRESSIVE ANTIBIOTICS nee Bokany Antonia Jekkel, Gabor Ambrus, Eva Toth-Sarudy, Istvan Mihaly, nee Dobos Agota Huiber, Attil Andor, Karol Albrecht, Kalman Konczol, Valeri Szell, nee Joszt Eva Tomori, Imre Moravcsik, Kalman Polya, Jano Erdei, Lajos Kiss, Bela Makadi, Karoly Nagy, Bel Palotas, nee Konszky Etelk Deli, Karoly Buzasi, nee Antal Aniko Santha Gyorgy Molnar, Vilma Szaszhegyesi, Budapest, Hungary assigned to Biogal Gyogyszergyar The invention relates to a microbial process for the production of immunosuppressive cyclosporine antibiotic complex or of its components, cyclosporine A, cyclosporine B and cyclosporine C, by the aerobic fermentation of a filamentous fungus strain biosynthesizing the above antibiotic(s) in a nutrient medium containing utilizable carbon and nitrogen sources as well as mineral salts, and by isolating the products formed, which comprises culturing a strain of the novel Tolypocladium varium fungus species producing the cyclosporine antibiotic complex, preferably tolypocladium varium sp. nov. CY/93, deposited at the National Collection of Agricultural and Industrial Microorganisms, Budapest, Hungary under the number NCAIM(P)F 001005, on a nutrient medium containing carbon sources, organic and inorganic nitrogen sources as well as mineral salts, under aerobic conditions, at 25 degrees to 30 degrees C., and, if desired, isolating and purifying the cyclosporine antibiotic complex or its components produced.
vii
of enhancing the activity of phagocytes including macrophages, and in a further variant, a method of modulating the cellular or humoral immune response to warm blooded animals. The invention also provides a method of reducing the adverse effects of stress in warm blooded animals. This is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M I-O-Y, an ethereal monosubstitution of monosaccharide derivatives having the general formula M2-O-Y, or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In the first variant, the above substances are administered in an amount effective to enhance the microbicidal activity of phagocytes, including macrophages in a normal to depressed state of activation or macrophages already activated in response to infection. In the second variant, the above substances are administered in an amount to enhance the cellular or humoral immune response when tile warm blooded animal has a normal or depressed cellular or humoral immune response system, or in an amount effective to reduce the cellular or humoral immune response when the warm blooded animal has a hypersensitive cellular or humoral immune response system. In the third variant, the above substances are administered in an amount effective to reduce the adverse effects of stress on the aforementioned defense mechanisms of warm blooded animals subjected to stress.
5158038 EGG INJECTION METHOD, APPARATUS AND CARRIER SOLUTION FOR IMPROVING HATCHABILITY AND DISEASE CONTROL Oliver B Sheeks, Raymond Sheeks
5157024 METHOD OF ENHANCING THE ACTIVITY OF PHAGOCYTES INCLUDING MACROPHAGES, MODULATING THE CELLULAR OR HUMORAL IMMUNE RESPONSE, AND REDUCING THE ADVERSE EFFECTS OF STRESS IN WARM BLOODED ANIMALS Pau Gordon assigned to Strategic Medical Research Corporation In one variant, the invention provides a method
An egg injection machine, beneficial injectable formulations for increasing the hatchability of avian hatchery eggs, and an improved method for the control of contamination in the injection process are provided. A novel ethanol-based contamination control carrier solution allows beneficial vaccines, vitamins, nutrients, and trace minerals to be injected into fertile eggs without risk of contamination of the eggs by machine, solution, or egg-to-egg crosscontamination by the injection needle. The invention is useful in both the chicken and turkey hatchery industry for egg injections prior to incubator setting or during transfer to hatch bins. Hatch improvements of + 2.29 percent to + 5.33
viii
New Patents
percent are shown for varying conditions. A method for facilitating the injections of virus vaccines is disclosed.
5158769 PRE-S GENE CODED PEPTIDE HEPATITIS B IMMUNOGENS, VACCINES, DIAGNOSTICS, AND SYNTHETIC LIPID VESICLE CARRIERS Alexander R Neurath, Stephen B Kent assigned to New York Blood Center Inc; California Institute of Technolo A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals. The peptides of the invention can be utilized in diagnostics for the detection of antigens and antibodies.
5158870 DIAGNOSTIC METHODS FOR MYCOPLASMA GENITALIUM INFECTIONS Joel B Baseman, Janice Morrison-Plummer assigned to Board of Regents The University of Texas System Monoclonal antibodies binding Mycoplasma genitalium more strongly than Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma orale, Mycoplasma salivarium and Acholeplasm laidlawii are described herein. These monoclonal antibodies are utilized in immunoassays directed toward the detection of M. genitalium infections. Hybridomas producing the above-described monoclonal anti-
bodies have been created and isolated. These monoclonal antibodies are directed toward M. genitalium antigens. Certain antibodies bind protein antigens, while others bind lipid antigens. In one case a particular antibody apparently has binding affinity for both protein and lipid antigens of M. genitalium.
5158884 IMMUNODOMINANT ACETYLCHOLINE RECEPTOR PEPTIDES USEFUL FOR THELPER CELL SENSITIZATION Bianca M Conti-Tronconi, Maria P Protti assigned to Regents of the University of Minnesota The present invention provides four synthetic peptides corresponding to subunits of the alphasubunit of the nicotinic acetyl choline receptor (AChR) which have formulas (1-4): (1) gln-il eval-thr-thr-asn-val-arg leu-lys-gln-gln-trp-valasp tyr-asn-leu-lys-trp; (2) ala-ile-val-lys-phe thr-lys-val-leu-leu-gln-tyrthr-gly-his-ile-thr-trpth r-pro; (3) ser-thr-his-val-met-pro-asn trp-valarg-lys-val-phe ile-asp-thr-ile-pro-as n; and (4) ile-ile-gly-thr-leu-ala val-phe-ala-gly-arg-leu-ile glu-leu-asn-gln-gln-gl y; as well as biologically active fragments thereof, and anti-AChR Thelper cell populations having receptor sites therefor.
5158940 USE OF SURAMIN TO TREAT RHEUMATOLOGIC DISEASES Renato LaRocca, Cy A Stein, Michael Cooper, Charles Myers assigned to The United States Government as represented by the Secretary DHHS Polysulfonated compounds such as suramin are used to treat immunoregulatory disorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.
5164320 METHOD FOR LYSING HARD LIPOSOMES USING POLYETHYLENEGLYCOL MONO-N-ALKYL ETHERS Herman Rutner, Abdul M Butt, Marie M Sylvestre, Josephine D Readio, Lewis Pollack assigned to Becton Dickinson and Company